Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On December 18, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (the “Subscr
Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in Item 1.01 of this Form 8-K are incorporated into this Item 3.02
, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities under, Section 18 of the Securities
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Subscription Agreement 10.2 Form of Registration Rights Agreement 99.1 Pre